Close Menu
Home › Medicare Covers Adaptive Biotechnologies' ClonoSeq Assay

Medicare Covers Adaptive Biotechnologies' ClonoSeq Assay

Jan 18, 2019
|
staff reporter

NEW YORK (GenomeWeb) – Adaptive Biotechnologies said after the close of the market on Thursday that Medicare contractor Palmetto GBA has established coverage of its next-generation sequencing-based assay, ClonoSeq, for Medicare patients with multiple myeloma and B-cell acute lymphoblastic leukemia.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Oct
03
Featured Webinar

Streamlined and High-Precision Cancer Analysis Using an Automated NGS Workflow in the Reference Lab Setting

This webinar will provide an overview of how an international reference laboratory has implemented an automated next-generation sequencing workflow with custom panels for analyzing cancer samples.

Oct
24
Featured Webinar

Designing, Decoding & Delivering on Genetic Testing for Inherited Disease at Versiti

This webinar will tell the story of Versiti’s journey in transforming genetic testing from a manual to a digitized process. It will include detail on how the organization succeeded, pain points along the way, a novel approach to variant assessment, and future plans for the program.

What's Popular?

In Sequencing

  1. Aperiomics Closes $1.8M Series A Round

  2. Canaccord Genuity, SVB Leerink Initiate Coverage of Castle Biosciences

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2019 GenomeWeb LLC.  All Rights Reserved.